Journal
CANCER CELL
Volume 7, Issue 2, Pages 129-141Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2005.01.007
Keywords
-
Categories
Funding
- NCI NIH HHS [CA36167, CA66996, CA86991] Funding Source: Medline
- NIDDK NIH HHS [DK50654] Funding Source: Medline
Ask authors/readers for more resources
The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a number of imatinib-resistant betacr-Abl mutants. Crystallographic analysis of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl. Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models. AMN107 is a promising new inhibitor for the therapy of CIVIL and Ph+ ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available